Development of biodegradable polymeric implants of RGD-modified PEG-PAMAM-DOX conjugates for long-term intratumoral release

References

• Anonymous. (1996). Gliadel wafer recommended for approval as treatment for brain cancer by FDA’S Oncologic Drugs Advisory Committee. Drug News Perspect 9:292
   Web of Science ®Google Scholar
• Aqil F, Jeyabalan J, Kausar H, et al. (2012). Multi-layer polymeric implants for sustained release of chemopreventives. Cancer Lett 326:33–40
   PubMed Web of Science ®Google Scholar
• Arias JL. (2011). Drug targeting strategies in cancer treatment: an overview. Mini Rev Med Chem 11:1–17
   PubMed Web of Science ®Google Scholar
• Badie B, Schartner JM. (2000). Flow cytometric characterization of tumor-associated macrophages in experimental gliomas. Neurosurgery 46:957–61
   PubMed Web of Science ®Google Scholar
• Beutler AS, Banck MS, Wedekind D, et al. (1999). Tumor gene therapy made easy: allogeneic major histocompatibility complex in the C6 rat glioma model. Hum Gene Ther 10:95–101
   PubMed Web of Science ®Google Scholar
• Bragagni M, Mennini N, Ghelardini C, et al. (2012). Development and characterization of niosomal formulations of doxorubicin aimed at brain targeting. Pharm Pharm Sci 15:184–96
   PubMed Web of Science ®Google Scholar
• Cai W, Niu G, Chen X. (2008). Imaging of integrins as biomarkers for tumor angiogenesis. Curr Pharm Des 14:2943–73
   PubMed Web of Science ®Google Scholar
• Fu YJ, Shyu SS, Su FH, et al. (2002). Development of biodegradable co-poly(d,l-lactic/glycolic acid) microspheres for the controlled release of 5-FU by the spray drying method. Colloid Surface B 25:269–79
   Web of Science ®Google Scholar
• Haaga JR, Exner AA, Wang Y, et al. (2005). Combined tumor therapy by using radiofrequency ablation and 5-FU-laden polymer implants: evaluation in rats and rabbits. Radiology 237:911–18
   PubMed Web of Science ®Google Scholar
• Herrmann S, Winter G, Mohl S, et al. (2007). Mechanisms controlling protein release from lipidic implants: effects of PEG addition. J Control Release 118:161–8
   PubMed Web of Science ®Google Scholar
• Holy CE, Dang SM, Davies JE, et al. (1999). In vitro degradation of a novel poly(lactide-co-glycolide) 75/25 foam. Biomaterials 20:1177–85
   PubMed Web of Science ®Google Scholar
• Jain RA. (2000). The manufacturing techniques of various drug loaded biodegradable poly(lactide-co-glycolide) (PLGA) devices. Biomaterials 21:2475–90
   PubMed Web of Science ®Google Scholar
• Jiang Z, Sun C, Yin Z, et al. (2012). Comparison of two kinds of nanomedicine for targeted gene therapy: premodified or postmodified gene delivery systems. Int J Nanomed 7:2019–31
   PubMed Web of Science ®Google Scholar
• Koocheki S, Madaeni SS, Niroomandi P. (2011). Development of an enhanced formulation for delivering sustained release of buprenorphine hydrochloride. Saudi Pharm J 19:255–62
   Web of Science ®Google Scholar
• Lesniak MS, Upadhyay U, Goodwin R, et al. (2005). Local delivery of doxorubicin for the treatment of malignant brain tumors in rats. Anticancer Res 25:3825–31
   PubMed Web of Science ®Google Scholar
• Li Y, He H, Jia X, et al. (2012). A dual-targeting nanocarrier based on poly(amidoamine) dendrimers conjugated with transferrin and tamoxifen for treating brain gliomas. Biomaterials 33:3899–908
   PubMed Web of Science ®Google Scholar
• Liu J, Shapiro JI. (2003). Endocytosis and signal transduction: basic science update. Biol Res Nurs 5:117–28
   PubMedGoogle Scholar
• Mesnukul A, Yodkhum K, Mahadlek J, et al. (2010). Characterization of indomethacin release from polyethylene glycol tablet fabricated with mold technique. Indian J Pharm Sci 72:92–100
   PubMed Web of Science ®Google Scholar
• Negrin CM, Delgado A, Llabres M, et al. (2004). Methadone implants for methadone maintenance treatment. In vitro and in vivo animal studies. J Control Release 95:413–21
   PubMed Web of Science ®Google Scholar
• Onishi H, Takahashi M, Machida Y. (2005). PLGA implant tablet of ketoprofen: comparison of in vitro and in vivo releases. Biol Pharm Bull 28:2011–15
   PubMed Web of Science ®Google Scholar
• Ojugo A, McSheehy P, McIntyre D, et al. (1999). Measurement of the extracellular pH of solid tumors in mice by magnetic resonance spectroscopy: a comparison of exogenous F-19 and P-31 probes. Nmr Biomed 12:495–504
   PubMed Web of Science ®Google Scholar
• Paun IA, Moldovan A, Luculescu CR, et al. (2011). Biocompatible polymeric implants for controlled drug delivery produced by MAPLE. Appl Surf Sci 257:10780–8
   Web of Science ®Google Scholar
• Puvanakrishnan P, Park J, Chatterjee D, et al. (2012). In vivo tumor targeting of gold nanoparticles: effect of particle type and dosing strategy. Int J Nanomed 7:1251–8
   PubMed Web of Science ®Google Scholar
• Ranganath SH, Fu Y, Arifin DY, et al. (2010). The use of submicron/nanoscale PLGA implants to deliver paclitaxel with enhanced pharmacokinetics and therapeutic efficacy in intracranial glioblastoma in mice. Biomaterials 31:5199–207
   PubMed Web of Science ®Google Scholar
• Santovena A, Alvarez-Lorenzo C, Llabres M, et al. (2009). hGH release from directly compressed hGH-PLGA biodegradable implantable tablets: influence of physicomechanical factors. Eur Polym J 45:2830–8
   Web of Science ®Google Scholar
• Shikanov A, Shikanov S, Vaisman B, et al. (2008). Paclitaxel tumor biodistribution and efficacy after intratumoral injection of a biodegradable extended release implant. Int J Pharm 358:114–20
   PubMed Web of Science ®Google Scholar
• Siegel R, Naishadham D, Jemal A. (2012). Cancer statistics. Ca-Cancer J Clin 62:10–29
   PubMed Web of Science ®Google Scholar
• Siegel SJ, Kahn JB, Metzger K, et al. (2006). Effect of drug type on the degradation rate of PLGA matrices. Eur J Pharm Biopharm 64:287–93
   PubMed Web of Science ®Google Scholar
• Sivak WN, Pollack IF, Petoud S, et al. (2008). LDI-glycerol polyurethane implants exhibit controlled release of DB-67 and anti-tumor activity in vitro against malignant gliomas. Acta Biomater 4:852–62
   PubMed Web of Science ®Google Scholar
• Stupp R, Hegi ME, van den Bent MJ, et al. (2006). Changing paradigms – an update on the multidisciplinary management of malignant glioma. Oncologist 11:165–80
   PubMed Web of Science ®Google Scholar
• Temming K, Schiffelers RM, Molema G, et al. (2005). RGD-based strategies for selective delivery of therapeutics and imaging agents to the tumour vasculature. Drug Resist Updat 8:381–402
   PubMed Web of Science ®Google Scholar
• Takahashi M, Onishi H, Machida Y. (2004). Development of implant tablet for a week-long sustained release. J Control Release 100:63–74
   PubMed Web of Science ®Google Scholar
• Vannucci L, Falvo E, Fornara M, et al. (2012). Selective targeting of melanoma by PEG-masked protein-based multifunctional nanoparticles. Int J Nanomed 7:1489–509
   PubMed Web of Science ®Google Scholar
• Voulgaris S, Partheni M, Karamouzis M, et al. (2002). Intratumoral doxorubicin in patients with malignant brain gliomas. Am J Clin Oncol-Canc 25:60–4
   PubMed Web of Science ®Google Scholar
• Wang CC, Li J, Teo CS, et al. (1999). The delivery of BCNU to brain tumors. J Control Release 61:21–41
   PubMed Web of Science ®Google Scholar
• Wang JX, Wang ZH, Chen JF, et al. (2008). Direct encapsulation of water-soluble drug into silica microcapsules for sustained release applications. Mater Res Bull 43:3374–81
   Web of Science ®Google Scholar
• Wang Q, Han Y, Jiang T, et al. (2011). MR Imaging of activated hepatic stellate cells in liver injured by CCl4 of rats with integrin-targeted ultrasmall superparamagnetic iron oxide. Eur Radiol 21:1016–25
   PubMed Web of Science ®Google Scholar
• Weinberg BD, Ai H, Blanco E, et al. (2007). Antitumor efficacy and local distribution of doxorubicin via intratumoral delivery from polymer millirods. J Biomed Mater Res A 81:161–70
   PubMed Web of Science ®Google Scholar
• Zhang C, Xie X, Liang S, et al. (2012). Mono-dispersed high magnetic resonance sensitive magnetite nanocluster probe for detection of nascent tumors by magnetic resonance molecular imaging. Nanomed-Nanotechnol Biol Med 8:996–1006
   PubMed Web of Science ®Google Scholar
• Zhang L, Zhu S, Qian L, et al. (2011). RGD-modified PEG-PAMAM-DOX conjugates: in vitro and in vivo studies for glioma. J Eur J Pharm Biopharm 79:232–40
   PubMed Web of Science ®Google Scholar
• Zhu S, Hong M, Tang G, et al. (2010a). Partly PEGylated polyamidoamine dendrimer for tumor-selective targeting of doxorubicin: the effects of PEGylation degree and drug conjugation style. Biomaterials 31:1360–71
   PubMed Web of Science ®Google Scholar
• Zhu S, Hong M, Zhang L, et al. (2010b). PEGylated PAMAM dendrimer-doxorubicin conjugates: in vitro evaluation and in vivo tumor accumulation. Pharm Res 27:161–74
   PubMed Web of Science ®Google Scholar
• Zhu S, Qian L, Hong M, et al. (2011). RGD-modified PEG-PAMAM-DOX conjugate: in vitro and in vivo targeting to both tumor neovascular endothelial cells and tumor cells. Adv Mater 23:H84–9
   PubMed Web of Science ®Google Scholar